Award
NIH Reporter #1ZIAAI001243-07
From therapeutic mechanisms to unraveling the pathophysiology of MS
Recipient
National Institute of Allergy and Infectious Diseases, United States
Award Amount
$1,402,526.00
Ceiling
$1,402,526.00
Awarded
April 27, 2024
Identifier
1ZIAAI001243-07
The award supports research to identify and target mechanisms driving MS progression independent of new lesions, using biomarker-guided personalized therapies to slow disability progression in progressive MS patients.
Description
This project focuses on understanding the mechanisms driving progression independent of lesional activity (PILA) in multiple sclerosis (MS) and testing personalized combination therapies to slow disability progression in patients with progressive MS. It includes research on the effects of clemastine fumarate and pioglitazone on CSF biomarkers and MS severity.